MOG and multiple sclerosis: The concomitant pharmacological down-regulation of the MyD88 signaling pathway was neuroprotective in vivo and attenuated inflammatory responses in the myelin oligodendrocyte glycoprotein (MOG) peptide induced experimental allergic encephalitis (EAE) model of multiple sclerosis (MS) [6].